equitymaster.comFalseFalseTATVA CHINTAN PHARMA - Last 8 Quarters |
|
Interim Results |
| No. of Months
Qtr. Ending | 3
Mar-22* | 3
Jun-22* | 3
Sep-22* | 3
Dec-22* | 3
Mar-23* | 3
Jun-23* | 3
Sep-23* | 3
Dec-23* |
Net Sales | Rs m | 985 | 884 | 901 | 1,206 | 1,245 | 1,144 | 967 | 842 |
Other income | Rs m | 3 | 19 | 19 | 11 | 8 | 10 | 8 | 12 |
Turnover | Rs m | 988 | 903 | 920 | 1,217 | 1,254 | 1,154 | 974 | 854 |
Expenses | Rs m | 765 | 732 | 789 | 1,027 | 1,082 | 930 | 764 | 732 |
Gross profit | Rs m | 220 | 152 | 112 | 179 | 127 | 213 | 202 | 110 |
Depreciation | Rs m | 21 | 23 | 23 | 24 | 25 | 60 | 68 | 66 |
Interest | Rs m | 12 | 11 | 18 | 24 | 32 | 29 | 30 | 4 |
Profit before tax | Rs m | 190 | 137 | 91 | 142 | 78 | 134 | 112 | 52 |
Tax | Rs m | 15 | 39 | 19 | 26 | -92 | 39 | 34 | 18 |
Profit after tax | Rs m | 175 | 98 | 71 | 116 | 170 | 95 | 78 | 35 |
Gross profit margin | % | 22.3 | 17.2 | 12.4 | 14.9 | 10.2 | 18.7 | 20.9 | 13.1 |
Effective tax rate | % | 7.7 | 28.5 | 21.5 | 18.3 | -117.3 | 29.2 | 30.6 | 34.1 |
Net profit margin | % | 17.8 | 11.1 | 7.9 | 9.6 | 13.6 | 8.3 | 8.0 | 4.1 |
Diluted EPS | Rs | 7.5 | 4.2 | 3.0 | 5.0 | 7.2 | 4.1 | 3.3 | 1.5 |
Diluted EPS (TTM) | Rs | 41.0 | 35.3 | 24.5 | 19.7 | 19.4 | 19.3 | 19.6 | 16.1 |
* Results Consolidated | Source: Company Annual Reports, Regulatory Filings, Equitymaster |
Interim results exclude extraordinary / exceptional items |